Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm Taiwan Total Payout Ratio Related Terms
Scinopharm Taiwan Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Total Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Total Payout Ratio of 0.00 as of Aug. 27, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Total Payout Ratio too high?
Scinopharm Taiwan's current Total Payout Ratio is 0.00. Overall, Scinopharm Taiwan has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Total Payout Ratio compare to ZTS?
Scinopharm Taiwan's Total Payout Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Drug Manufacturers company?
A good Total Payout Ratio depends on the Drug Manufacturers industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.16, compared to a current price of NT$19.05 — trading 5.5% below its estimated fair value. The current Total Payout Ratio is 0.00. Scinopharm Taiwan's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Total Payout Ratio is 0.00 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.05 is trading 5.5% below its estimated GF Value™ of NT$20.16.
GuruFocus considers Scinopharm Taiwan to be Fairly Valued.
Key valuation signals for TPE:1789:
Total Payout Ratio: 0.00
GF Value™: NT$20.16 vs. price of NT$19.05 (5.5% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
73GF Score
Get the complete analysis for TPE:1789
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
